Remimazolam: A Novel Option for Procedural Sedation in High Risk Patients
Journal of Pharmacy Practice · 2023-02 · 36 (1) · 149-154
DOI: 10.1177/08971900211027303 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy Practice, online erschienen am 22.06.2021. Verfasst von Megan M Pantos und 2 weiteren Autor:innen. Beteiligte Einrichtung: 307289Western New England University, College of Pharmacy and Health Sciences, Springfield, MA, USA. Hauptthemen laut MEDLINE: Midazolam, Benzodiazepines. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Purpose
The purpose of this drug review was to explore the safety and efficacy of the newly approved benzodiazepine, remimazolam, in order to evaluate its place in therapy. Summary: Remimazolam has a faster onset of action and recovery time than midazolam when given as single IV doses. Additionally, it has no known CYP450 interactions that would contribute to drug-drug interactions. Patients with severe hepatic impairment may require dose titration as well as the elderly who should be closely monitored. Although remimazolam vials should be protected from light and must be reconstituted immediately before use, the reconstituted vial may be stored for later use at room temperature for up to 8 hours. Remimazolam is more expensive than current options used in practice, as such individual institutional formulary and provider preference will require review to see if its advantages are worth the additional cost and to determine its place in therapy.
Conclusion
Remimazolam is a novel option when choosing a benzodiazepine for procedural sedation that has pharmacokinetic and pharmacodynamic advantages when compared to other commonly prescribed sedatives. Remimazolam has proved superior to midazolam when analyzing drug-drug interactions, onset, and time to alertness. Remimazolam also has a shorter elimination half-life and decreased volume of distribution when compared to midazolam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 307289Western New England University, College of Pharmacy and Health Sciences, Springfield, MA, USA.
- 501438Sacred Heart University, College of Health Professions, Fairfield, CT, USA.
ORCID-Profile: Eric C Nemec
Zitieren
APA
Pantos, M. M., Kennedy, D. R., & Nemec, E. C. (2023). Remimazolam: A Novel Option for Procedural Sedation in High Risk Patients. Journal of Pharmacy Practice, 36(1), 149-154. https://doi.org/10.1177/08971900211027303
Vancouver
Pantos MM, Kennedy DR, Nemec EC. Remimazolam: A Novel Option for Procedural Sedation in High Risk Patients. Journal of Pharmacy Practice. 2023;36(1):149-154. doi:10.1177/08971900211027303
BibTeX
@article{Pantos2023,
author = {Pantos, Megan M and Kennedy, Daniel R and Nemec, Eric C},
title = {Remimazolam: A Novel Option for Procedural Sedation in High Risk Patients},
journal = {Journal of Pharmacy Practice},
year = {2023},
volume = {36},
number = {1},
pages = {149--154},
doi = {10.1177/08971900211027303}
}
EUVIMED